Article Text

PDF
Characterisation of an OCS-dependent severe asthma population treated with mepolizumab
  1. C M Prazma1,
  2. S Wenzel2,
  3. N Barnes3,4,5,
  4. J A Douglass6,
  5. B F Hartley7,
  6. H Ortega1
  1. 1GlaxoSmithKline, Research Triangle Park, North Carolina, USA
  2. 2Division of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  3. 3Respiratory Medical Franchise, GSK, Uxbridge, UK
  4. 4The William Harvey Research Institute, Barts, London, UK
  5. 5The London School of Medicine and Dentistry, London, UK
  6. 6Department of Allergy and Immunology, The Royal Melbourne Hospital and The University of Melbourne, Parkville, Victoria, Australia
  7. 7GlaxoSmithKline, Uxbridge, UK
  1. Correspondence to Dr Hector Ortega, GlaxoSmithKline, 5 Moore Drive, PO Box 3317.3A, Research Triangle Park, NC 27709-3398, USA; hector.g.ortega{at}gsk.com

Abstract

A subpopulation of patients with asthma treated with maximal inhaled treatments is unable to maintain asthma control and requires additional therapy with oral corticosteroids (OCS); a subset of this population continues to have frequent exacerbations. Alternate treatment options are needed as daily use of OCS is associated with significant systemic adverse effects that affect many body systems and have a direct association with the dose and duration of OCS use. We compared the population demographics, medical conditions and efficacy responses of the OCS-dependent group from the DREAM study of mepolizumab with the group not managed with daily OCS.

Trial Registration Number NCT01000506.

  • Asthma
  • Eosinophil Biology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.